Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024)

Alto Neuroscience (ANRO) posted Total Non-Current Liabilities of $26.1 million for Q4 2024, down 1.78% sequentially from $26.6 million in Q3 2024, and up 68.59% YoY from $15.5 million in Q1 2024.

Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends

Alto Neuroscience has reported Total Non-Current Liabilities for 2 years, with the latest figure at $26.1 million in Q4 2024.

  • Quarterly Total Non-Current Liabilities rose 68.59% year-over-year to $26.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $26.1 million (up 68.59% YoY) and the FY2024 annual result came in at $26.1 million, up 68.59% from the prior year.
  • Total Non-Current Liabilities declined to $26.1 million in Q4 2024 per ANRO's latest filing, from $26.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $26.6 million in Q3 2024 and troughed at -$1.7 million in Q1 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Alto Neuroscience 1.13 Bn 1.13 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 26.08 Mn
Sep 30, 2024 26.56 Mn
Jun 30, 2024 17.58 Mn
Mar 31, 2024 16.82 Mn
Dec 31, 2023 15.47 Mn
Sep 30, 2023 -1.40 Mn
Jun 30, 2023 -1.60 Mn
Mar 31, 2023 -1.70 Mn